Clinical Trials Logo

Facial Lipoatrophy clinical trials

View clinical trials related to Facial Lipoatrophy.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT03050749 Completed - Facial Lipoatrophy Clinical Trials

Safety and Performance of Princess® VOLUME for the Treatment of Facial Lipoatrophy, Asymmetry or Scars

FLASH2
Start date: November 20, 2016
Phase: N/A
Study type: Interventional

In this study, eligible patients with the medical indications (facial lipoatrophy, morphological asymmetry of the face, or debilitating scars) will be treated with Princess® VOLUME, and then will return for follow-up assessments 2, 4, 24, and 36 weeks after the treatment. A touch-up treatment may be done 2 weeks after the treatment if deemed appropriate by the Investigator.

NCT ID: NCT03050723 Completed - Facial Lipoatrophy Clinical Trials

Safety and Performance of Princess® FILLER for the Treatment of Facial Lipoatrophy, Asymmetry or Scars

FLASH 1
Start date: November 20, 2016
Phase: N/A
Study type: Interventional

In this study, eligible patients with the medical indications (facial lipoatrophy, morphological asymmetry of the face, or debilitating scars) will be treated with Princess® FILLER, and then will return for follow-up assessments 2, 4 and 24 weeks after the treatment. A touch-up treatment may be done 2 weeks after the treatment.

NCT ID: NCT00360932 Completed - Facial Lipoatrophy Clinical Trials

Facial Lipoatrophy Correction Experience With SCULPTRA ("FACES" Study)

FACES
Start date: October 2005
Phase:
Study type: Observational

5 year, open-label study to evaluate safety of SCULPTRA on the signs of lipoatrophy of the face in at least 100 evaluable subjects with human immunodeficiency virus.

NCT ID: NCT00333684 Completed - Clinical trials for Human Immunodeficiency Virus

Safety, Efficacy and Psychological Effects of Treating Antiretroviral Drug-Induced Facial Lipoatrophy With Bio-Alcamid

Start date: December 2004
Phase: Phase 2
Study type: Interventional

Evaluate and record any changes in the Quality of Life and psychological state of the affected study group following treatment with Bio-Alcamid. Evaluate the safety and efficacy of Bio-Alcamid for restoring the natural fullness and contours of the face affected by HIV drug-induced lipoatrophy. Pre-treatment classification and post treatment recording of changes will be performed by, both, the Principal Investigator and the Treatment Specialist and independently by a 'Blinded' Co-Investigator at post treatment Week 12. Safety data for Bio-Alcamid will be collected throughout the duration of the study. Safety will be determined by the rates of procedure-related events and adverse experiences associated with the use of Bio-Alcamid.